A new injection for tough-to-treat lupus
This study tests an investigational drug called ACG102, given as an injection, for people with active lupus that hasn't improved with standard treatments. The goal is to see if it can help control the disease and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have been diagnosed with systemic lupus erythematosus (SLE), a condition where your immune system attacks your own body.
- Your lupus must be active and not responding well to usual treatments, or it has come back after getting better.
- You need to be on a stable dose of your current lupus medicines for at least 4 weeks before starting the study.
- You must not have had certain serious infections, liver problems, heart issues, or cancer in the last 5 years.
- You must not have recently used certain other biologic treatments for lupus, and you cannot be allergic to any part of the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called SYS6020 for people whose lupus is still active despite standard treatments. It aims to see if the drug can help reduce lupus activity.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
This trial tests a new treatment called ACE1831 for people with moderate to severe lupus that has not improved with standard treatments like steroids or other medications. The goal is to see if it can help control lupus activity.
This study tests an investigational injection called AFN50 for people whose lupus (SLE) remains active despite standard treatments. The goal is to see if the drug can safely help control lupus symptoms better than current therapies alone.
This trial tests an experimental injection called ZM001 for people with refractory systemic lupus erythematosus (SLE) who haven't gotten better after standard treatments. It aims to see if ZM001 can help control moderate to severe disease activity.
Hear when a new Refractory Active Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.